Schmidt-Rhode P, Schulz K D, Sturm G, Raab-Frick A, Prinz H
Department of Obstetrics and Gynecology, Philipps University Marburg (Lahn), Germany FR.
Int J Biol Markers. 1987 Sep-Dec;2(3):135-42. doi: 10.1177/172460088700200301.
CA 15.3 is an antigenic determinant associated with human mammary carcinomas. Two murine monoclonal antibodies have been raised against the determinants, and an immunoradiometric assay (IRMA-Kit, Centocor, USA) has been developed to determine the antigen levels in plasma of cancer patients. Based on the 99% confidence limit of healthy women, plasma values above 30 U/ml are considered abnormal. Plasma samples from 357 women were examined in the present study. Healthy females (n = 84) ranged below the cut-off level between less than 10 and 29 U/ml. Higher values were found in 12.5% of benign breast diseases and in 23.6% of breast cancer patients, including all stages. Depending on the stage of the disease, there were elevated levels in 11% of operable breast cancer patients preoperatively, in 7% of the cases with no evidence of disease after primary treatment and in 63.5% of patients with disseminated mammary carcinoma. In metastasized breast cancer the frequency and the degree of abnormal titers were closely related to the extent of the metastatic disease. Follow-up examinations of 63 patients under cytotoxic therapy showed CA 15.3 changes correlating well with the clinical course in up to 90% of the antigen positive cases. The present data indicate that CA 15.3 may be useful in the surveillance of breast cancer patients. However in our study one third of the patients with metastatic breast cancer did not show any increase in CA 15.3 and must be regarded as antigen negative.
CA 15.3是一种与人类乳腺癌相关的抗原决定簇。已经制备了两种针对该决定簇的鼠单克隆抗体，并开发了一种免疫放射分析方法（IRMA试剂盒，美国Centocor公司）来测定癌症患者血浆中的抗原水平。以健康女性99%的置信限为依据，血浆值高于30 U/ml被认为异常。本研究检测了357名女性的血浆样本。健康女性（n = 84）的值低于临界值，在10至29 U/ml之间。在12.5%的良性乳腺疾病患者和23.6%的乳腺癌患者（包括所有分期）中发现了更高的值。根据疾病分期，可手术乳腺癌患者术前11%的患者水平升高，初次治疗后无疾病证据的患者中7%的患者水平升高，播散性乳腺癌患者中63.5%的患者水平升高。在转移性乳腺癌中，异常滴度的频率和程度与转移疾病的范围密切相关。对63名接受细胞毒性治疗的患者进行的随访检查显示，在高达90%的抗原阳性病例中，CA 15.3的变化与临床病程密切相关。目前的数据表明，CA 15.3可能有助于监测乳腺癌患者。然而，在我们的研究中，三分之一的转移性乳腺癌患者CA 15.3没有任何升高，必须被视为抗原阴性。
